Today: 3 May 2026
Browse Category

NYSE:LLY 27 September 2025 - 2 November 2025

Eli Lilly Stock Pre-Market Preview: Will Obesity-Drug Boom Send LLY to New Highs? (Nov 3, 2025)

Eli Lilly Stock Pre-Market Preview: Will Obesity-Drug Boom Send LLY to New Highs? (Nov 3, 2025)

Eli Lilly shares closed near $863 on Oct. 31, up about 10% for the month and close to a 52-week high. Q3 revenue jumped 54% to $17.6 billion, driven by surging demand for GLP-1 drugs Mounjaro and Zepbound, with U.S. GLP-1 market share at 57%. Management raised 2025 sales and EPS guidance sharply. The company recently won FDA approval for Inluriyo and expanded Walmart access for Zepbound.
2 November 2025
·
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly Stock on Fire: GLP-1 Bonanza, Big Earnings & AI Pivot Drive Rally

Eli Lilly reported Q3 2025 revenue of $17.60 billion, up 54% year-over-year, and raised full-year EPS guidance to $23.00–23.70. Shares closed at $813.53 on Oct. 29, down 2% over the week after hitting highs above $850 earlier in the month. The FDA approved Inluriyo for metastatic breast cancer, and the EU cleared Kisunla for early Alzheimer’s. Wall Street’s average 12-month price target stands near $939.
30 October 2025
···
Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Over 62,000 pharmaceutical professionals from more than 170 countries are attending CPHI Frankfurt 2025, where executives are meeting to address global supply chain, regulation, and innovation challenges. Eli Lilly’s GLP-1 drugs generated $6.1 billion in Q1 2025, overtaking Novo Nordisk in the U.S. weight-loss drug market. Pharma giants are investing heavily as the global obesity treatment market is projected to reach $100 billion by 2030.
28 October 2025
····
Adverum (ADVM) Stock Skyrockets on News of Lilly’s $12.47/Share Gene Therapy Deal

Adverum (ADVM) Stock Skyrockets on News of Lilly’s $12.47/Share Gene Therapy Deal

Eli Lilly said Oct. 24 it will buy Adverum Biotechnologies for $3.56 per share plus a CVR worth up to $8.91, targeting Adverum’s lead gene therapy Ixo-vec for wet AMD. Adverum shares jumped 17% on the news but stayed well below the $12.47 maximum deal value. The agreement includes a $65 million secured loan to fund trials before closing. Adverum had warned its cash would run out by Q4 2025.
24 October 2025
···
Stocks to Buy Today (Oct. 22, 2025): Top Picks as Markets Near Record Highs

Stocks to Buy Today (Oct. 22, 2025): Top Picks as Markets Near Record Highs

U.S. stock indexes hover near record highs after the Dow gained 0.5% Tuesday, while the Nasdaq slipped 0.2% on tech earnings misses. About 85% of S&P 500 companies have beaten forecasts, the highest rate in four years. AMD surged to record highs on AI chip deals, while Eli Lilly hit $935 on obesity drug demand. Netflix fell 6–7% pre-market after an earnings miss; Texas Instruments dropped nearly 9% on weak guidance.
22 October 2025
···········
Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Therapeutics shares jumped 17% to $30.35 on Oct. 20, 2025, marking their highest level since early 2024. The rally followed bullish technical signals and positive clinical updates for its gene-editing therapies. Analysts at Jefferies and H.C. Wainwright reiterated Buy ratings, with price targets up to $80. Beam ended Q2 with $1.2 billion in cash, enough to fund operations into 2028.
20 October 2025
·····
Nasdaq’s Wild Week: Tech Titans Soar & Plunge as Volatility Spikes – What’s Next?

Nasdaq’s Wild Week: Tech Titans Soar & Plunge as Volatility Spikes – What’s Next?

The Nasdaq closed at 22,679.98 Friday, up 117 points, capping a volatile week near record highs. Nvidia shares retreated after hitting records, while AMD jumped 34% on an OpenAI chip deal. The KBW Regional Bank Index rebounded after sharp losses as banks addressed loan and fraud concerns. The VIX spiked to a six-month high before easing, with traders bracing for volatility ahead of major tech earnings and a delayed U.S. inflation report.
18 October 2025
·········
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Surges on Obesity Drug Boom and Alzheimer’s Breakthroughs – Is $1,000 Next?

Eli Lilly shares hit a record $832 intraday on Oct. 1, fueled by demand for its obesity drugs and Alzheimer’s advances, before slipping 4% after Donald Trump pledged to cut weight-loss drug prices. Lilly’s Mounjaro and ZepBound now hold 57% of U.S. GLP-1 prescriptions, outpacing Novo Nordisk. First-half 2025 revenue jumped about 40% year-on-year. Most analysts remain bullish, despite valuation and policy concerns.
17 October 2025
··
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly Stock Rockets on GLP‑1 Boom and New Approvals: Is LLY the Next Trillion‑Dollar Pharma Titan?

Eli Lilly stock opened at $840.46 on Oct. 6, 2025, after a 9% surge the previous week, with a market cap near $795 billion and P/E ratio around 55. Q2 revenue rose 38% to $15.56 billion, led by Mounjaro and Zepbound, and Lilly raised 2025 guidance to $60–62 billion revenue. The company announced over $1 billion investment in India manufacturing and received European approval for Kisunla in early Alzheimer’s.
6 October 2025
·
Shutdown Drags On But Wall Street Hits Records – Here’s What’s Driving Markets

Shutdown Drags On But Wall Street Hits Records – Here’s What’s Driving Markets

The S&P 500 and Dow closed at record highs despite a second week of U.S. government shutdown, while the Nasdaq lagged as tech shares wavered. Key economic data releases were delayed, forcing traders to rely on private surveys showing continued labor market weakness. Markets expect the Federal Reserve to cut rates in October. Japan’s Nikkei hit a record after a pro-stimulus leader’s election, and gold reached $3,944 an ounce.
6 October 2025
····
Bitcoin Blasts Past $125K, AI Wars Escalate, and Space Tech Soars – Global Tech Roundup (Oct 5–6, 2025)

Bitcoin Blasts Past $125K, AI Wars Escalate, and Space Tech Soars – Global Tech Roundup (Oct 5–6, 2025)

Bitcoin surged past $125,000 to a record high as investors poured in. Elon Musk’s xAI and OpenAI filed lawsuits against each other, with OpenAI calling Musk’s claims “harassment.” Tesla teased an Oct. 7 event for a cheaper electric car. Firefly Aerospace agreed to buy defense firm SciTec for $855 million to expand military space work.
6 October 2025
··········
U.S. Stocks Rally as Shutdown Fears Fade – Markets Hit Fresh Records

U.S. Stocks Rally as Shutdown Fears Fade – Markets Hit Fresh Records

All three major U.S. indexes closed at record highs on Oct. 1, with the S&P 500 topping 6,700 for the first time. ADP reported U.S. private payrolls fell by 32,000 in September, fueling bets on two Fed rate cuts by year-end. The 10-year Treasury yield dropped to 4.10%, gold hit a record near $3,895, and healthcare stocks surged after a Trump–Pfizer price deal. Lithium Americas soared 23% after a U.S. government investment.
2 October 2025
······
Market Record Rally Amid Shutdown: A Deep Dive into U.S. Stock Performance on 1 October 2025

Market Record Rally Amid Shutdown: A Deep Dive into U.S. Stock Performance on 1 October 2025

U.S. stocks closed at record highs despite a partial government shutdown, with the S&P 500 up 0.34% to 6,711.20 and the Dow rising 0.09% to 46,441.10. Health-care shares jumped after Pfizer and the White House struck a drug price deal, sending Biogen up 10.9%. The ADP report showed private-sector jobs fell by 32,000 in September, but investors bet on Fed rate cuts.
1 October 2025
·····
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

The Federal Reserve cut rates by 25 basis points to 4.00–4.25% in mid-September, citing slowing growth as inflation remains above target. The S&P 500 is up about 13% in 2025, but strategists warn valuations are high. Compass agreed to buy Anywhere for $4.2 billion in stock, sending Anywhere shares up nearly 49%. The U.S. implemented a new auto trade pact with the EU, lowering tariffs to 15% as of August 1.
28 September 2025
·············
Billion-Dollar AI Bets and Biotech Breakthroughs: Top Tech News (Sept 27–28, 2025)

Billion-Dollar AI Bets and Biotech Breakthroughs: Top Tech News (Sept 27–28, 2025)

Nvidia will invest up to $100 billion to build 10 gigawatts of AI data centers for OpenAI, with the first 1 GW due by late 2026. The US cybersecurity agency issued an emergency directive after hackers breached at least one federal agency via Cisco firewall flaws, affecting hundreds of devices. The FDA approved Eli Lilly’s new breast cancer drug Inluriyo. The SEC loosened ETF rules, opening the door for new crypto ETFs.
28 September 2025
·········
Nasdaq’s Wild Week: AI Mega-Deal Hype, Tariff Turmoil, and Tech Titans on Edge

Nasdaq’s Wild Week: AI Mega-Deal Hype, Tariff Turmoil, and Tech Titans on Edge

The Nasdaq snapped a three-week win streak despite a Friday rebound, closing at 22,484, down 0.6% for the week. Trump announced new tariffs on trucks, pharma, and furniture, sending Paccar up 5.2% and RH down 4%. Nvidia signaled a $100 billion OpenAI investment, fueling a semiconductor rally. Core inflation matched forecasts at 2.7% year-on-year in August.
27 September 2025
··········
Wall Street Rebound: Fed Relief, Tariff Twists & Tech Surprises (NYSE Highlights Sept 26–27, 2025)

Wall Street Rebound: Fed Relief, Tariff Twists & Tech Surprises (NYSE Highlights Sept 26–27, 2025)

U.S. stocks rebounded Friday, with the Dow up 0.7%, S&P 500 0.6%, and Nasdaq 0.4%, but all three still posted weekly losses. August core PCE inflation matched forecasts at 0.2%. The Fed cut rates for the first time since December and signaled more cuts possible. Trump announced new tariffs on trucks, drugs, and furniture, boosting shares of Paccar and Eli Lilly.
27 September 2025
······
1 … 9 10 11 12

Stock Market Today

  • Top UK Stocks to Buy Now: AstraZeneca and Unilever Lead the Picks
    May 3, 2026, 3:19 AM EDT. With the average British saver holding £9,633.30 in low-yield bank accounts, investing in stocks could offer better returns over time. Experts highlight AstraZeneca for its strong oncology pipeline and ambitious $80 billion revenue target by 2030 despite risks like US drug pricing reforms and investigations in China. Unilever is also favored for its robust growth and defensive qualities, currently undergoing a major restructuring by spinning off its food division and merging with McCormick. However, concerns remain over the merger's execution and potential shareholder pushback. Both stocks present opportunities and risks amid a challenging economic backdrop.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 03.05.2026

3 May 2026
Rivian shares fell 8.4% to $15.02 after first-quarter results beat expectations, as investors focused on cash burn and profitability concerns. Trading volume jumped 78% above average. The company plans to ramp up R2 SUV production in Georgia to 300,000 units annually. Tesla and Lucid Group shares both rose more than 2%.
Vertiv Stock Tests AI Data-Center Rally as VRT Shares Hit Fresh Highs

Vertiv Stock Tests AI Data-Center Rally as VRT Shares Hit Fresh Highs

3 May 2026
Vertiv shares hit a 52-week high Friday before closing at $328.31, following a 30% jump in Q1 net sales to $2.65 billion. The company raised its 2026 outlook and recently acquired Strategic Thermal Labs, expanding its liquid cooling portfolio. Investors await further details at Vertiv’s May 19-20 conference in South Carolina.
AT&T Inc. Raises $6 Billion as 5G and Fiber Bet Enters a Debt Test

AT&T Inc. Raises $6 Billion as 5G and Fiber Bet Enters a Debt Test

3 May 2026
AT&T closed a $6 billion sale of long-dated notes on April 30, with maturities ranging from 2033 to 2066, according to an SEC filing. The company reported first-quarter free cash flow of $2.5 billion, down from $3.1 billion a year earlier, citing higher capital investment. AT&T is preparing to close a $23 billion purchase of EchoStar spectrum licenses. CFO Pascal Desroches said net debt to adjusted EBITDA rose to 2.71 times.
Go toTop